The treatment of EGFR-mutated NSCLC with EGFR tyrosine kinase inhibitors (TKIs) is a model of biomarker-based therapy and highlights the importance of establishing a predictive molecular biomarker for personalized therapy in the treatment of solid tumors [5]. Here, EGFR is linked to non-small cell lung carcinoma.